Potential First-in-Class Live Biotherapeutics
New Hope for Patients with Chronic Kidney Disease
Kibow Therapeutics is a clinical-stage developer of live biotherapeutics for persons with chronic kidney disease (CKD). The Company is advancing potential first-in-class therapies to selectively modulate the gut microbiome to improve kidney function and quality of life. Kibow Therapeutics is focused first on KT-301, an encapsulated consortium of proprietary strains of commensal bacteria targeting uremic toxins associated with CKD. Phase 2 clinical studies in CKD patients are underway to assess KT-301’s safety and its ability to halt or slow progression of CKD. Kibow Therapeutics is headquartered in Newtown Square, PA.
Harnessing Live Biotherapeutics
Helpful bacteria are necessary for overall health and not just bowel health. Harmful microorganisms found in the gut may contribute to the progression of certain diseases. A disturbance of gut microbiota is known as dysbiosis.
Development Programs in Kidney Disease
We are advancing potential first-in-class live biotherapeutics for CKD and ESRD. A Phase 2 clinical study in CKD patients is underway to assess KT-301’s safety and its ability to slow progression of kidney disease.